SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT00570297

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Genetic Influences of Albuterol Response In Children With Bronchiolitis

Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 hospitalizations per year in the U.S. Recently, genetic variations of the β2-adrenergic receptor (β2-AR) have been shown to influence response to β2-AR agonist therapy in children with asthma. We suspect that genetic variations of the β2-AR also affect response to β2-AR agonist therapy in children with bronchiolitis.

NCT00570297 Bronchiolitis
MeSH: Bronchiolitis
HPO: Bronchiolitis


Primary Outcomes

Measure: The primary end point is change in lung resistance following a single dose of inhaled b2-AR agonist therapy (albuterol).

Time: Immediate

Secondary Outcomes

Measure: To assess the change in lung compliance following a single dose of inhaled b2-AR agonist therapy (albuterol)

Time: Duration of hospitalization

Measure: To compare duration of mechanical ventilation and ICU hospital length of stay by genotype

Time: Duration of Hospitalization

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 E27Q

The next most common polymorphism of the β2-AR gene, glutamine to glutamic acid at position 27 (Glu27Gln), may be associated with the development of asthma and airway hyperresponsiveness, but these relationships are less clear. --- Glu27Gln ---



HPO Nodes


HPO:
Bronchiolitis
Genes 7
SDCCAG8 PLCG2 TAP1 PLEC TAP2 TAPBP SLC35C1